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Background: Host determinants of severe coronavirus disease 2019 include advanced age, comorbidities and
male sex. Virologic factors may also be important in determining clinical outcome and transmission rates,
but limited patient-level data is available.
Methods: We conducted an observational cohort study at seven public hospitals in Singapore. Clinical and
laboratory data were collected and compared between individuals infected with different SARS-CoV-2 clades.
Firth’s logistic regression was used to examine the association between SARS-CoV-2 clade and development
of hypoxia, and quasi-Poisson regression to compare transmission rates. Plasma samples were tested for
immune mediator levels and the kinetics of viral replication in cell culture were compared.
Findings: 319 patients with PCR-confirmed SARS-CoV-2 infection had clinical and virologic data available for
analysis. 29 (9%) were infected with clade S, 90 (28%) with clade L/V, 96 (30%) with clade G (containing
D614G variant), and 104 (33%) with other clades ‘O’ were assigned to lineage B.6. After adjusting for age and
other covariates, infections with clade S (adjusted odds ratio (aOR) 0¢030 (95% confidence intervals (CI):
0¢00020¢29)) or clade O (B¢6) (aOR 0¢26 (95% CI 0¢0640¢93)) were associated with lower odds of develop-
ing hypoxia requiring supplemental oxygen compared with clade L/V. Patients infected with clade L/V had
more pronounced systemic inflammation with higher concentrations of pro-inflammatory cytokines, chemo-
kines and growth factors. No significant difference in the severity of clade G infections was observed (aOR
0¢95 (95% CI: 0¢352¢52). Though viral loads were significantly higher, there was no evidence of increased
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pro-inflammatory cytokines. Infection with clade G was not associated with changes in severity, and despite
higher viral loads there was no evidence of increased transmissibility.
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)enza data (GISAID)
f four major SARS-
e ORF3a coding pro-
ike protein S-D614G
lectively called clade
and L are the earliest
2019/January 2020
Wuhan outbreak. G
and L remain genet-
des” is assigned for
efinitions, in which
on (e.g. B.6) can be
es this nomenclature
ot attempt to reflect
of the virus. A litera-
to October 23, 2020
irus disease 2019;
614G. Viruses con-
G) have become the
March 2020, and in
may be more infec-
ed the prevalence of
tient level data was
utcomes of all four
CR-confirmed SARS-
with clade L/V, the
plemental oxygen in
ge B.6) were signifi-




was no evidence of
al loads (as indicated
ificantly higher with
e of increased trans-
tness in cell culture
with a more severe
-inflammatory cyto-
(B.6). No increased
es was observed, and
ificantly higher than
ased infectivity. Fur-
lications for develop-1. Introduction
The severity of coronavirus disease 2019 (COVID-19) ranges from
asymptomatic infection to pneumonia, critical illness and death
[13]. Major determinants of disease severity include host age, pre-
existing comorbidities and sex, but virologic factors may also be
important [4,5]. The characterisation of a severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) variant with a 382-nucletide
deletion in open reading frame 8 (ORF8) and its association with
milder clinical illness is illustrative [6]. However, currently clinical
comparison of the transmissibility and virulence of common SARS-
CoV-2 variants is lacking. The recent emergence of several variants of
concerns (VOC) in South Africa and the UK, and suspected implica-
tions for the effectiveness of vaccines and monoclonal antibody ther-
apeutics highlights the importance of this type of analysis [7].
Several classification schemes have been introduced to describe the
diversity of SARS-CoV-2 viruses [8]. The global initiative on sharing all
influenza data (GISAID) nomenclature describes four major SARS-CoV-2
clades in the early outbreak: clade L, clade V (variant of the ORF3a cod-
ing protein NS3-G251), clade G (variant of the spike protein S-D614G
with further subclades GR, GH and GV collectively called clade G here),
and clade S (variant ORF8-L84S). S and L are the earliest known clades,
co-occurring from December 2019 to January 2020, with Clade L being
characteristic of theWuhan outbreak. G and V clades are descendants of
L, though V and L remain genetically closely related [9]. Nextstrain
nomenclature offers a similar high level annotation, while SARS-CoV-2
lineages (cov-lineages.org) provide amore granular viewwith hundreds
of named lineages incorporating epidemiological and sequence infor-
mation corresponding to outbreaks in different regions [10]. The high-
level GISAID clades described above cover 97¢5% of all strains while the
rest are labelled as “O” for “Other clades” in which case the more
detailed lineage information (e.g. B.6) can be used.
The various SARS-CoV-2 nomenclatures are generally in agreement
in their categorisation of genetic diversity but importantly, they do not
attempt to reflect antigenic or other phenotypic properties of the virus.
Viruses containing the genetic variant G614 (G-clade) have become the
most common reported worldwide since March 2020, leading to the
hypothesis that this variant is more infectious [11]. However, the cur-
rent dominance of G614 viruses may reflect a founder effect, while
country-level data correlating the prevalence of G614 with mortality
requires a more detailed study [1214]. Whether other clades are asso-
ciated with phenotypic differences is unknown.
Singapore experienced a wide diversity of SARS-CoV-2 clade infec-
tions over the first three months of the pandemic, with cases imported
from China, Europe, the United Sates and other major travel routes [15].
We aim to compare clinical outcomes and transmissibility following
infection with different SARS-CoV-2 clades using patient-level data gen-
erated through comprehensive contact tracing, case finding and isola-
tionmeasures in Singapore since the beginning of the local outbreak.2. Methods
2.1. Study design and participants
Details of the first 10,000 COVID-19 cases in Singapore (from Jan-
uary 22 to April 22, 2020), by date of notification were extracted
from the Ministry of Health database and matched with SARS-CoV-2
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supplementary file for acknowledgment table) [16]. Detailed clinical
information was obtained from all patients who were participants of
a multi-centre prospective observational cohort study conducted at
seven major public hospitals in Singapore (Appendix p1). Over the
first three months of the COVID-19 pandemic this study attempted to
recruit all individuals admitted with virologically-confirmed SARS-
CoV-2 infection. Serial blood samples were collected from consenting
participants during hospitalisation and post-discharge. Clinical data
was obtained from a review of medical records. In addition, we
obtained clinical data from a retrospective study of all patients with
COVID-19 who were admitted to the National Centre for Infectious
Diseases, the main infectious diseases management centre in Singa-
pore.
2.2. Epidemiological investigation and testing
All COVID-19 cases were interviewed by the Singapore Ministry of
Health to determine activity histories from 14 days preceding
symptom onset until isolation in hospital, including recent travel
history and possible contact with confirmed cases. Contact tracing
was also initiated to identify contacts who had significant interac-
tions with each case. Active case finding through testing of symp-
tomatic contacts was performed to detect additional COVID-19
cases amongst these contacts and amongst travellers quarantined
on arrival in Singapore. In addition, COVID-19 testing was man-
dated for persons meeting suspect case definitions, including per-
sons who presented with pneumonia and influenza-like illnesses
[17].
2.3. Estimating transmissibility by clade
The number of secondary cases that resulted from each case was
derived from the epidemiological findings of all 10,000 cases. It was
calculated through repeated probabilistic sampling (1000 repetitions)
based on the assumption that in a cluster with 3 or more cases, cases
with symptoms onset after an index case could have acquired the
infection from the index case or from other secondary case(s). We
determine the possible parent infectors for an offspring infectee after
factoring for (a) the serial intervals between the infectee and all other
possible infectors and (b) the overall serial interval distribution that
we have observed amongst cases in Singapore [15]. Only symptom-
atic cases were considered.
For estimating transmissibility clades for cases that were not gen-
otyped were imputed from those of epidemiologically linked cases
that were gentoyped. Clusters with more than one clade implicated
were excluded. The number of secondary cases amongst cases with
assigned viral clade were analysed for associations between viral
clade and disease transmissibility. Due to significantly different trans-
mission patterns, cases in the dormitory setting where there are large
outbreaks were excluded in the analysis of secondary transmission.
2.4. Clinical management
Over the course of this study, all patients with COVID-19 were iso-
lated with airborne transmission precautions regardless of disease
severity. Supplemental oxygen was administered for pulse oximeter
saturations  94%. Patients with moderate to severe hypoxia (defined
as requiring fraction of inspired oxygen [FiO2]  40%) were trans-
ferred to the intensive care unit (ICU) for high-flow oxygen via nasal
cannula and invasive mechanical ventilation as required. De-isolation
was contingent on two consecutive nasopharyngeal swabs > 24 h
apart that were negative for SARS-CoV-2 by polymerase chain reac-
tion (PCR).2.5. Correlation with clinical outcomes
Primary endpoint was the proportion of patients who developed
severe COVID-19, defined as hypoxia requiring supplemental oxygen.
This endpoint was selected due to the low incidence of ICU admission
or death in Singapore. Secondary outcomes were the levels of
immune mediators in plasma samples and the SARS-CoV-2 viral load
as defined by the PCR cycle threshold (Ct) value from the first avail-
able nasopharyngeal swab. Other clinical outcomes are exploratory.
2.6. Viral RNA sequencing and clade determination
SARS-CoV-2 PCR was performed with a range of commercially
available assays used at the participating hospitals. Sequencing of
SARS-CoV-2 was performed in one of four laboratories in Singapore
together with GISAID submission and case matching. Pangolin
COVID-19 Lineage Assigner and CoVsurver were used to assign line-
age and clade to each sequence, respectively [10,18]. For analysis, L
and V clades were merged given their close genetic relatedness, simi-
larly G, GH and GR were merged (Appendix p2; GV had not been
described at this point in the pandemic). Sequences labelled as ‘O’
(other clades) were analysed based on assigned Pangolin lineage.
2.7. SARS-CoV-2 culture
Nasopharyngeal swabs were used to inoculate Vero-E6 cells for
virus isolation in an Animal Biological Safety Level 3 (ABSL3) labora-
tory. Cells were cultured at 37 °C until cytopathic effect (CPE) was
observed. Positive isolation was confirmed by the observation of CPE
and virus-specific PCR. Following virus isolation, virus stocks were
prepared in Vero-E6 cells.
For virus growth kinetics, Vero-E6 cells were seeded into 12-well
plates at a density of 2 £ 105 cells per well. Cells were infected with
the respective viruses at a multiplicity of infection (MOI) of 0¢01.
Cell-associated virus was harvested at 24, 48, 72 and 96 h post-infec-
tion and titrated by limiting dilution on Vero-E6 cells and are
expressed as the 50% tissue culture infectious dose (TCID50) per milli-
litre.
2.8. Multiplex microbead-based immunoassay
Levels of specific immune mediators in the first plasma samples
collected during hospitalisation were quantified by multiplex
microbead-based immunoassays. Plasma samples were treated with
1% TritonTM X-100 for virus inactivation [19]. Immune mediator lev-
els were measured with the LuminexTM assay using the Cytokine/
Chemokine/Growth Factor 45-plex Human ProcartaPlexTM Panel 1
(ThermoFisher Scientific, Waltham, MA) (Appendix p3). Patient sam-
ples with concentrations out of measurement range were assigned
the value of logarithmic transformation of Limit of Quantification
(LOQ). Data analysis was conducted with Bio-Plex ManagerTM 6.1.1
software (Bio-Rad, Hercules, CA).
2.9. Data processing and statistical analysis
Kruskal-Wallis test and Conover's post-hoc pairwise multiple
comparison test (for continuous variables) and chi-square test (for
categorical variables) were used to compare characteristics and out-
comes between groups. Firth’s logistic regression was used to exam-
ine the association between the SARS-CoV-2 clade and development
of hypoxia due to the presence of separation with zero cell frequency
of hypoxia for a particular clade. The following covariates were
selected for inclusion in the multivariable logistic regression model:
age group, sex, comorbidities, diagnosis through active case finding,
month of COVID-19 diagnosis and clade/lineage. An multivariable
ordinal regression model was also developed using the same
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1 = pneumonia, no hypoxia, 2 = hypoxia requiring supplemental oxy-
gen, 3 = critical illness and/or death. A quasi-Poisson regression was
used to examine the association between SARS-CoV-2 clades and
transmission rate, using the number of secondary cases resulting
from a case as the dependant variable and the days between disease
onset to isolation as an offset to the linear predictor. The latter is
used as a surrogate for the period of transmissibility, the true period
of which is generally longer due to pre-symptomatic transmission.
Subsequent adjustment was performed for this model, for age (repre-
sented by three bands: < 45 years (referent), 4564 years and  65
years) and sex (male as referent).
One-way analysis of variance (ANOVA) followed by post-hoc t-test
with Bonferroni correction was performed on the logarithmically
transformed concentrations in order to discern the differences in
immune mediator levels amongst patients with different SARS-CoV-2
clade infections. Heatmap and plots were generated using GraphPad
Prism version 8 (San Diego, CA). In the heat map presentation, the
concentrations of immune mediators were scaled between 0 and 1
for visualisation.
Data processing and analysis were done in the R statistical lan-
guage (version 3.6.1) and Stata version 15 (StataCorp, College Station,
TX). All statistical tests were two-sided, and p-values < 0¢05 consid-
ered statistically significant. Adjustment for multiple testing was not
performed.
2.10. Ethics statement
The epidemiological investigation was conducted under the Infec-
tious Diseases Act (Singapore). Study protocols were approved by
ethics committees of the National Healthcare Group and SingHealth.
Written informed consent was obtained from participants for clinical
data and biological sample collection as part of the PROTECT study
(2012/00917; 2018/3045). A waiver of informed consent for retro-
spective data collection only was granted for individuals admitted to
the National Centre of Infectious Diseases (2020/01122). Healthy
donor samples were collected under study numbers 2017/2806 and
NUS IRB 04-140.Fig. 1. Epidemiological curve of COVID-19 cases, Sin2.11. Role of the funding source
This study was funded by grants from the Singapore National
Medical Research Council (COVID19RF-001, COVID19RF2-0001, COV-
ID19RF-007, and COVID19RF-60) and Biomedical Research Council
(project number H20/04/g1/006). The funders had no role in the
design and conduct of the study; collection, management, analysis
and interpretation of the data; preparation, review or approval of the
manuscript; and decision to submit the manuscript for publication.
The corresponding authors have full access to all the data in the study
and take responsibility for the integrity of the data and the accuracy
of the data analysis.
3. Results
3.1. Descriptive epidemiology
The first confirmed COVID-19 case in Singapore was an imported
infection notified on January 22, 2020, and the first locally transmit-
ted cases were reported on February 3, 2020 (Fig. 1). In response to
the outbreak travel restrictions were progressively introduced from
February 1, 2020 and a heighted disease alert level was announced
on February 7, 2020. A surge in imported cases occurred in March
2020 when residents returned from overseas, with entry-restrictions
and 14-day quarantine for arrivals imposed on affected countries.
The first foreign worker dormitory cluster was announced at the end
of March 2020. This spread to involve numerous foreign worker dor-
mitories, resulting in a steep increase in cases that peaked at more
than 1000 cases per day by late April 2020. The increase in cases trig-
gered social distancing restrictions on March 26, 2020, with broad
restrictions imposed from April 7, 2020 similar to the lockdowns in
other countries.
Of the first 10,000 COVID-19 cases reported in Singapore, 8132
(81¢3%) were male foreign workers residing in dormitories. Overall,
the proportion of elderly cases (age 65 and above) was 2¢4% (240/
10,000); decreasing from 11¢0% (98/865) in January to March, to 1¢5%
(134/9033) in April 2020. 0¢2% (23/10,000) died with COVID-19 listed
as a direct cause. 540 of the first 10,000 cases had SARS-CoV-2gapore, January 22 to April 21, 2020 (n = 9956).
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ing. The four major clades, S, L, V and G were all present in Singapore
in January 2020 with repeated importation and local clusters of infec-
tion until April 2020. The large outbreak amongst foreign workers
was almost exclusively due to O (B.6) [20].
3.2. Cohort study
320/540 (59%) patients with genotyped virus had detailed clinical
data available for analysis (Appendix p1). 29 (9%) were clade S, of
which 18 (62%) were known to be infected with the attenuated D382
variant (Table 1). 67 (21%) were infected with clade L, 23 (7%) with
clade V, and 96 (30%) with clade G (of which 33 were GH and 41 GR).
104 (33%) infections with O label (other clades) were assigned to line-
age B.6, while one infection with lineage B.4 was excluded from fur-
ther analysis.
Overall, the cohort for analysis of 319 individuals included 47
(15%) with severe infection (hypoxia with requirement for supple-
mental oxygen) and 23 (7%) with critical illness (Table 1). 89% of the
cohort was aged less than 65 years, and 82% had a Charlson’s comor-
bidity index of 0. 47% of the cohort was diagnosed through activeTable 1.
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Co-morbid conditionsk 78 (24%) 3 (10%)
Laboratory values
LDH 383 (328461) 369 (321418)
CRP 5¢3 (1¢715¢1) 5¢0 (1¢311¢7)
Lymphocyte count 1¢3 (0¢91¢8) 1¢3 (1¢01¢6)
Neutrophil count 2¢9 (2¢14¢0) 2¢3 (2¢03¢3)
Ct Value 24¢6 (21¢129¢6) 26¢8 (23¢431¢5)
Outcomes
Pneumonia 122 (38%) 10 (34%)
Supplemental oxygen 47 (15%) 0 (0%)
ICU/Death 23 (7%) 0 (0%)
Data is presented as median (inter-quartile range) or n (%) unless indicated.
CRP: C-reactive protein; ICU: intensive care unit; LDH: lactate dehydrogenase.
* One case (lineage B.4) excluded.
y 23 Jan to 29 Feb 2020.
z Including contact tracing, quarantine orders and surveillance.
x India, Bangladesh, Sri Lanka.
k Categorical variable defined as Charlson Comorbidity Index 1 or hypertensioncase finding, a proportion that did not significantly change from Janu-
ary to April (January/February, 26/49 (53%); March 82/189 (43%);
April 41/82 (50%), p = 0¢95, Chi square for trend). There was no signif-
icant change in the crude proportion of individuals with severe infec-
tion from January to April (January/February 11/49 (22%); March 25/
189 (13%); April 11/82 (13%), p = 0¢25, Chi square for trend).
Significant baseline differences between the groups infected with
different clades were observed  including in age, ethnicity and
comorbidities. After adjusting for co-variates in the multivariable
logistic regression model, compared with L/V there was no significant
difference in the severity of G-clade infection, while infections with
clade S (adjusted odds ratio (aOR) 0¢030 (95% confidence intervals
(CI): 0¢00020¢29)) or clade O (B.6) (aOR 0¢26 (95% CI 0¢0640¢93))
were associated with lower odds of developing hypoxia requiring
supplemental oxygen compared with infection (Table 2). There were
30 dormitory residents amongst the 104 individuals infected with O
(B.6) in the cohort, none of whom had severe infection (dormitory: 0/
30 (0%), non-dormitory: 12/74 (16%)). After excluding dormitories
residents from the analysis, infections with O (B.6) remained signifi-
cantly less severe compared with L/V (aOR 0¢29 (95% CI 0¢0711¢00),
p = 0¢049, Appendix p4).L/V G O (B.6) p-value
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27 (30%) 13 (14%) 35 (34%) 0¢0014
405 (339532) 370 (312428) 383 (332457) 0¢032
7¢6 (2¢623¢7) 5¢0 (1¢512¢5) 4¢4 (1¢712¢8) 0¢083
1¢1 (0¢91¢7) 1¢1 (0¢91¢4) 1¢5 (1¢12¢1) <0¢0001
2¢9 (2¢13¢7) 3¢0 (2¢13¢9) 3¢1 (2¢24¢3) 0¢052
25¢7 (22¢030¢4) 21¢9 (19¢126¢4) 25¢8 (23¢730¢7) < 0¢0001
45 (50%) 33 (34%) 34 (33%) 0¢060
24 (27%) 11 (11%) 12 (12%) 0¢0007
14 (16%) 0 (0%) 9 (9%) 0¢0002
. See Appendix p4 for breakdown of comorbid conditions by clade.
Table 2
Odds ratios of candidate predictors for (a) hypoxia requiring supplemental oxygen from Firth’s logistic regression analysis, and (b) clinical outcome ordered from
mild infection to critical illness and/or death frommultivariable ordinal logistic regressiony.
Univariable LR model Multivariable LR model Proportional odds modely























Female sex 0¢84 (0¢431¢57) 0¢58 0¢70 (0¢331¢47) 0¢35 0.85 (0.501.44) 0.55





















































aOR: adjusted odds ratio; CI: confidence interval; LR: Logistic regression; OR: odds ratio.
y Outcomes ordered as: 0=mild (no pneumonia), 1=pneumonia, no hypoxia, 2=hypoxia requiring supplemental oxygen, 3=critical illness and/or death. Propor-
tional odds assumption examined with Brant test: parallel regression assumptions holds for individual variables and overall model (p = 0.92).
z Categorical variable defined as Charlson Comorbidity Index  1 or hypertension.
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Acute plasma samples at the first collection timepoint upon hospi-
tal admission were available from 99 patients (Fig. 2a). No significant
difference in the sample collection time point was observed between
the different clades (Appendix p6). Collectively, higher concentra-
tions of chemokines MCP-1, RANTES, SDF-1a, and IP-10, pro-inflam-
matory IFN-g , IL-6 and IL-1b and the anti-inflammatory IL-1RA were
detected in patients infected with clades L and V compared withFig. 2. Plasma immune mediator levels of COVID-19 patients infected with different SARS-Co
microbead-based immunoassay. (a) Heatmap of immune mediator levels in plasma sample
n = 10; clade G, n = 22; clades L and V, n = 46) during first collection timepoint upon hospita
concentration of a particular analyte. Blue and red indicates low and high concentration, re
with different SARS-CoV-2 clades at the first collection timepoint upon hospital admission a
first collection timepoint during hospital admission (median 5 days from symptom onset)
way ANOVA followed by post-hoc t-test with Bonferroni correction was performed on th
Immune mediator levels for healthy controls (n = 23) are indicated by the black dotted line. P
of logarithm transformation of Limit of Quantification (For interpretation of the references topatients infected with either clade S or G (Fig. 2b) at a median of 5
days post-illness onset (interquartile range 38). In addition, these
patients had higher levels of growth factors associated with lung
injury and regeneration, including SCF, VEGF-A, PIGF-1 and PDGF-BB.
Notably, patients infected with clade G SARS-CoV-2 had lower con-
centrations of growth factors including VEGF-A, HGF, PDGF-BB and
PIGF-1, pro-inflammatory IL-1b, IFN-g and chemokines such as
RANTES, SDF-1a and IP-10, at the early acute phase of infection
(Fig. 2B).V-2 clades. Concentrations of 45 immune mediators were quantified using a 45-plex
s of patients infected with different SARS-CoV-2 clades (clade S, n = 21; clade O (B.6),
l admission (median 5 days from symptom onset). Each colour represents the relative
spectively. (b) Profiles of significant immune mediators of COVID-19 patients infected
re illustrated as scatter plots. Immune mediator levels in plasma fraction samples from
were compared amongst the patients infected with different SARS-CoV-2 clades. One-
e logarithmically transformed concentration (*p < 005; **p < 001; **p < 00001).
atient samples with concentration out of measurement range are presented as the value
color in this figure legend, the reader is referred to the web version of this article.).
Table 3.
Relative risk of onward transmission (i.e. any secondary transmission) by clade
amongst non-dormitory cases with genotyped and inferred clades (n = 587).
Crude RR (95%CI) p-value Adjusted RR (95%CI) p-value
Clade
L/V 1¢00 (reference) - 1¢00 (reference) -
S 1¢28 (0¢941¢73) 0¢12 1¢28 (0¢941¢75) 0¢12
G 0¢35 (0¢230¢56) < 0¢001 0¢36 (0¢230¢58) < 0¢001
O (B.6) 0¢78 (0¢611) 0¢048 0¢80 (0¢621¢02) 0¢07
Age Group (Years)
< 45 1¢00 (reference) - 1¢00 (reference) -
4564 1¢17 (0¢931¢47) 0¢19 1¢11 (0¢891¢39) 0¢34
 65 1¢07 (0¢761¢5) 0¢70 1¢02 (0¢731¢44) 0¢91
Female sex 1¢24 (11¢53) 0¢048 1¢19 (0¢971¢46) 0¢10
Note:Modified Poisson regression with binary outcome of transmission occurrence as
regressand, amongst those who were exposed to the community after symptom onset.
CI: confidence interval; RR: relative risk.
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In addition to the 540 cases with SARS-CoV-2 genotyping infor-
mation available, a further 5626 cases had virus genotype inferred by
epidemiologically linkages. The majority (5460/6166, 88¢6%) were
dormitory residents and were excluded from the analysis. amongst
706 cases included in the analysis (Appendix p78), the average
number of secondary transmissions was 0¢34, with lowest in clade G
(0¢11) (Appendix p9). After adjusting for age and gender, the trans-
mission rate was also lowest in G, with an adjusted transmission rate
ratio of 0¢40 (95%CI: 0¢230¢71, p = 0¢002) compared to clades L/V.
The difference in the risk of transmission between clades L/V and the
other clades were not statistically significant (Table 3).
3.5. Viral culture
There was no significant difference between the viral loads of
Clade L/V, S and O (B.6), whereas Clade G was associated withFig. 3. Kinetics of viral replication of 16 SARS-CoV-2 virus isolates up to 96 h post-significantly higher viral loads compared with the other three clades
(Conover post hoc pairwise comparison, p < 0.05). Day of sample col-
lection was not significantly different (KruskalWalis, p = 0.64). The
kinetics of viral replication in cell culture were similar between the
different clades as measured up to 96 h after inoculation (Fig. 3).
4. Discussion
In this large cohort study we found no evidence for attenuated or
increased severity of clade G when comparing infections with the L/V
clades. However, clade G was associated with significantly higher
viral loads (as measured by PCR Ct value). Clade S was associated
with less severe infection, likely reflecting infection by the ORF7/8
deletion variant that we previously reported to be associated with
attenuated severity [6]. O (B.6) was associated with attenuated sever-
ity of infection for reasons that are unclear and merits further investi-
gation.
G-clade viruses emerged in late January 2020 and became the
most common clade worldwide (based on samples submitted to
GISAID) in March 2020 [21]. To date there is little patient level data
comparing outcomes from G-clade viruses with other variants. A
study of 999 patients in Sheffield, UK, reported that infection with
G614 was not associated with an increased risk of hospital admission,
however, it was associated with higher viral load [22]. A study of 113
infections in Hong Kong reported no significant increase in the sever-
ity of infection [23]. We found that clade G is not associated with dif-
ferent disease severity compared with L/V.
The significantly lower PCR Ct value with G-clade infection
observed in our cohort supports other data that this virus may be
more infectious [24]. In vitro experiments indicate that the G614 vari-
ant opens the structure of the spike protein, facilitating binding to the
ACE-2 receptor and that this virus is more infectious in tissue culture
[21,25]. While previous studies have used a pseudovirus, we
observed no difference in viral kinetics between G and other clades.
In a hamster model, the SARS-CoV-2 virus with the G614 virusinfection. S 3 isolates; L/V 7; G, 5; O (B.6). TCID: Tissue culture infectious dose.
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lungs, than the D614 virus [26].
At the same time, we observed significantly lower transmission
from individuals infected with G-clade viruses compared with other
clades. This is likely to be due to significantly earlier isolation of this
group, and may reflect either improvements in community diagnosis
or behavioural differences in then affected population. For all clades
the reproduction number, R, was significantly below 1, and overall
0¢34 reflecting the success of Singapore’s COVID-19 public health
measures at reducing transmission in the community and indicating
that these interventions are effective regardless of clade [15]. While
an underestimate because only symptomatic infections are consid-
ered, it is still low compared to other R values estimated from symp-
tomatic infections [27]. Higher SARS-CoV-2 viral load has been
correlated with COVID-19 mortality, suggesting host immune
response to G-clade infections may differ and be less pathogenic 
either as a direct result of D614G or other genetic variation associated
with this clade [28,29].
We found patients infected with clade L/V had more pronounced
systemic inflammation with higher concentrations of pro-inflamma-
tory cytokines, chemokines and growth factors that are strongly asso-
ciated with severe COVID-19 during the early acute phase of infection
[30,31]. Excessive production of pro-inflammatory cytokines in SARS-
CoV-2 infection damages endothelial cells resulting in capillary leak-
age and vascular injury [32]. The more robust production of pro-
inflammatory IL-1b, IL-6, MCP-1, RANTES and MIP-1 b at the early
phase of infection observed in patients infected with clade L/V could
promote lung damage, which may in turn result in severe clinical
outcomes, as shown by the higher proportion of patients in this
group requiring oxygen. Intriguingly, those with clade G infections
had a less overactive inflammatory response [22]. In addition,
patients with clade S infections had lower levels of inflammation
compared with those infected with L/V, and this may reflect the
known association between the ORF8 deletion variant and inflamma-
tory responses [6].
This observational study has a number of limitations. We only
included data up to April 2020, a period which saw the greatest
diversity of SARS-CoV-2 clades in Singapore. Viral adaptation to
infection in humans may have occurred since then which affects
COVID-19 severity. We also merged several closely genetically
related clades (L/V and G/GH/GR) to improve study power which pre-
vents us from analysing the effects of these individual clades. SARS-
CoV-2 testing during the study period was largely symptom driven
and it is possible that asymptomatic or pauci-symptomatic infection
rates vary with different clades. As the pandemic progressed beyond
March 2020 the cohort study was unable to enrol all individuals with
COVID-19 due to the large numbers. Recruitment was biased towards
more severe infections, suggesting that for G and O (B.6) clades in
particular severity is likely to have been overestimated. Clinical man-
agement evolved over the first few months of the pandemic which
may have improved outcomes. However, it remained largely support-
ive: remdesivir was yet to be licensed, corticosteroids were avoided,
while convalescent plasma and monoclonal antibodies were not
available [33,34]. SARS-CoV-2 PCR was performed on different com-
mercial platforms, with varied gene targets, limiting the comparabil-
ity of Ct values. Also, clade distribution in the population is
associated with certain subpopulations and clusters. As such, associa-
tions of severity with clades may reflect underlying human behaviour
or characteristics in the subpopulations, rather than the true viru-
lence or infectiousness of the virus. These differences are difficult to
measure and challenging to control for in an observational study.
SARS-CoV-2 genotypes imputed through epidemiological linkage
data risks misclassification. However, the community disease inci-
dence in Singapore was low (e.g. 0.7 per 100,000 persons per day in
April 2020) in a setting of aggressive contact tracing. As a result it
was unlikely that infection within a cluster arose from more than onesource of infection providing high confidence in the relationships
between cases. Furthermore, clusters with more than one genotyped
clade were excluded. While there may be uncertainties in determin-
ing the exact direction of transmission within a cluster, a probabilistic
approach to transmission was undertaken. A limitation is that only
symptomatic cases were considered in assessing transmissibility, as
this allows greater confidence in the direction of transmission. The
results may not necessarily reflect the transmissibility of asymptom-
atic disease unless the clade distribution of asymptomatic cases is
similar to that of symptomatic disease.
In conclusion, as a newly emerged human pathogen, SARS-CoV-2
is likely to be under strong selection pressure to adapt to infection in
humans. The recent emergence of new variants which may also be
able to evade host immunity is concerning, though claims of
increased transmissibility or changes in virulence require careful
evaluation [35]. In our large cohort study, with detailed epidemiolog-
ical, clinical and immunological data we find patient-level evidence
that infections by G-clade viruses are associated with higher viral
titres, without necessarily affecting disease severity or increasing
transmissibility. The association of O (B.6) infections with attenuated
severity and stronger immune response as compared to early L/V vs
later G-clades is intriguing but requires further study.
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